| TECHNOLOGY |
Co do intend to bring anthrax lethal factor (ALF) inhibitors all the way through. Although it's hoped that the market for anthrax therapies will never be large, "it is attractive for a small company simply because it doesn't take enormous resources to serve. "It would probably be impossible to build a company only on products of this nature, but it's a good way to expand our revenue stream and maybe work on a few additional biodefense projects." Co. has just received a $750,000 Phase II small-business innovation research grant from NIH. Using its "genes-to-lead" technology, the company has created small-molecule inhibitors of ALF, the toxin produced in the body by anthrax spores.
"We believe we can have an anthrax drug on the market within four years."
|